Abstract
Subject. Drug-associated jaw osteonecrosis is a serious complication that can occur in patients receiving bisphosphonate therapy for bone metastases in malignant neoplasms. The studies are due to the widespread use of bisphosphonates in patients with proven bone metastases, with myeloma, and malignant neoplasms of various locations. Due to the toxic effects of bisphosphonates on soft tissues, the healing process is sluggish, often with a relapse. The task of finding optimal methods of stimulating local regenerative processes is urgent, since the use of general-action drugs can provoke continued growth of the primary tumor. The aim of the study was to develop a method for treating patients with a diagnosis of “drug-associated jaw osteonecrosis” using autologous plasma, which will further reduce the number of relapses and increase the effectiveness of treatment. Methodology. Patients with a diagnosis of “medically associated jaw osteonecrosis” underwent sequestrectomy with boundaries determined by perfusion by laser Doppler flowmetry, an APRF clot was placed on the bottom of the bone wound, and autologous plasma was injected into the wound edges in the postoperative period. Results. The result of applying this technique in the early postoperative period was a partial discrepancy of the edges of the wound, but the absence of sections of the exposed bone in the wound. After 6–8 weeks, we observed complete healing of the postoperative wound. The number of relapses was reduced from 16 to 3 (by 57.56 %). Conclusions. The use of autologous plasma in the treatment of drug-associated osteonecrosis is the most optimal way to stimulate local regenerative processes in the absence of the possibility of using general-action drugs.
Highlights
Patients with a diagnosis of “medically associated jaw osteonecrosis” underwent sequestrectomy with boundaries determined by perfusion by laser Doppler flowmetry, an APRF clot was placed on the bottom of the bone wound, and autologous plasma was injected into the wound edges in the postoperative period
Гистологическая оценка ткани выявила снижение экспрессии гена р63, что указывает на снижение базальных предшественников клеток и может привести к нарушению заживления слизистой оболочки полости рта [19]
Summary
ПРИМЕНЕНИЕ АУТОЛОГИЧНОЙ ПЛАЗМЫ ПРИ ЛЕЧЕНИИ МЕДИКАМЕНТОЗНО АССОЦИИРОВАННОГО ОСТЕОНЕКРОЗА ЧЕЛЮСТЕЙ Цель исследования — разработать метод лечения пациентов с диагнозом «медикаментозно ассоциированный остеонекроз челюсти» с применением аутологичной плазмы, способствующий в дальнейшем снижению количества рецидивов и повышению эффективности лечения. Пациентам с диагнозом «медикаментозно ассоциированный остеонекроз челюсти» проводили секвестрэктомию с определением границ по показателям перфузии методом лазерной допплеровской флоуметрии, на дно костной раны укладывали сгусток APRF, в послеоперационном периоде проводили инъекции аутологичной плазмы в края раны.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
